GlassScriptPhysician profile
Mary T Self
NPI 1306882170
$14,037.43
in general payments reported to CMS, 2019-2025
59 companies · $2,469 in 2025
The $2,469 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,387 · 2020: $1,459 · 2021: $1,569 · 2022: $2,347 · 2023: $1,847 · 2024: $1,959 · 2025: $2,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,264 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,264.34 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,885.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,249.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $1,117.29 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Insulet Corporation | $938.70 | 2019-2025 | Omnipod |
| Amgen INC. | $635.82 | 2019-2025 | Repatha, Tepezza, Repatha |
| Amarin Pharma, INC. | $591.69 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $526.66 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $515.98 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $473.90 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $372.01 | 2019-2025 | |
| Corcept Therapeutics | $358.87 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.96 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Recordati_rare_diseases_inc. | $289.24 | 2021-2025 | Isturisa |
| Dexcom, INC. | $279.09 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $275.77 | 2019-2025 | Synthroid |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $271.21 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $262.03 | 2025 | Eluvia, Ekosonic |
| Alexion Pharmaceuticals, INC. | $244.17 | 2021-2025 | Strensiq |
| Medtronic, INC. | $242.34 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $219.34 | 2019-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $206.11 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $177.01 | 2023-2025 | Yorvipath |
| Pfizer INC. | $169.15 | 2023-2024 | |
| Horizon Therapeutics Plc | $159.05 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.04 | 2019-2023 | Cycloset |
| Shire North American Group INC | $155.85 | 2019 | |
| Antares Pharma, INC. | $145.86 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $139.04 | 2021-2025 | |
| Medtronic Minimed, INC. | $131.35 | 2019-2020 | |
| Mannkind Corporation | $110.64 | 2020-2022 | |
| Becton, Dickinson and Company | $97.88 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $95.30 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $94.50 | 2025 | Camzyos |
| Neurocrine Biosciences, INC. | $92.17 | 2025 | |
| Companion Medical, INC. | $83.83 | 2019 | |
| Eusa Pharma (US) LLC | $81.41 | 2022 | |
| Ibsa Pharma INC. | $66.42 | 2019-2023 | Tirosint, Licart |
| Janssen Pharmaceuticals, INC | $62.61 | 2019-2020 | |
| Sequel Med Tech, LLC | $60.33 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $48.16 | 2019 | |
| Grt US Holding, INC. | $46.75 | 2022 | |
| Beta Bionics, INC. | $45.81 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $45.79 | 2023 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $43.15 | 2020-2021 | |
| Kyowa Kirin, INC. | $41.79 | 2023 | Crysvita |
| Eisai INC. | $40.60 | 2019 | |
| Chiesi USA, INC. | $40.20 | 2024-2025 | Mycapssa |
| Lifescan, INC. | $36.12 | 2021-2023 | |
| Endo Pharmaceuticals INC. | $35.53 | 2021 | |
| Amryt Pharma Holdings LTD | $35.28 | 2023 | Mycapssa |
| Halozyme INC | $33.72 | 2023 | |
| Rgh Enterprises LLC | $32.90 | 2025 | |
| Zealand Pharma US, INC. | $25.16 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $24.20 | 2019 | |
| Almatica Pharma LLC | $18.09 | 2025 | Loreev Xr |
| Amphastar Pharmaceuticals, INC. | $16.91 | 2025 | |
| Alfasigma USA, INC. | $15.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.26 | 2020 | |
| Radius Health, INC. | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Self listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.